

# MCL Pathway at a Glance

Six-stage MDT pathway from diagnosis to follow-up · MHA-MCL-2026-v1.6.0

## 1 Diagnosis

### Confirm the diagnosis

- Tissue biopsy
- Cyclin D1 (BCL1)
- SOX11 IHC
- t(11;14) FISH if cyclin D1 negative
- Morphological variant (classical / blastoid / pleomorphic / leukaemic non-nodal)

## 2 Biology

### Risk-stratify

- Ki-67 (percentage)
- TP53 IHC pattern AND NGS
- MIPI / MIPI-c
- Morphological variant
- Complex karyotype
- Assign MDT risk category

## 3 Fitness

### Assess fitness

- ECOG performance status
- Clinical Frailty Scale
- Renal function (eGFR)
- Cardiac assessment
- Transplant suitability
- Comorbidity burden

## 4 Access

### Check access

- NICE TA status
- Local formulary
- NHS England commissioning
- Clinical trial availability
- Compassionate access / IFR / EAMS

## 5 MDT Decision

### Categorise & document

- A. Routine**  
Current UK standard
- B. Evolving access-dependent**  
Practice-changing evidence
- C. Selected alternative**  
Frailty / palliative
- D. Not routine**  
Historical / no evidence

## 6 Follow-up

### Follow-up

- Response assessment
- Surveillance (clinical + bloods; symptom-led imaging)
- Supportive care (vaccination, Ig, PJP)
- Re-biopsy at relapse
- Re-test TP53 at relapse

⚠ **Evidence-supported does not equal NHS-commissioned. Verify current NICE / local commissioning / SmPC at the point of every decision.**